PE20200340A1 - Compuestos heteroaromaticos como inhibidores de vanina - Google Patents

Compuestos heteroaromaticos como inhibidores de vanina

Info

Publication number
PE20200340A1
PE20200340A1 PE2019002531A PE2019002531A PE20200340A1 PE 20200340 A1 PE20200340 A1 PE 20200340A1 PE 2019002531 A PE2019002531 A PE 2019002531A PE 2019002531 A PE2019002531 A PE 2019002531A PE 20200340 A1 PE20200340 A1 PE 20200340A1
Authority
PE
Peru
Prior art keywords
heteroaromatic compounds
alkyl
vanin
compound
formula
Prior art date
Application number
PE2019002531A
Other languages
English (en)
Inventor
Todd Bosanac
Michael J Burke
Brian Nicholas Cook
Darren Todd Disalvo
Jr Thomas Martin Kirrane
Yue Shen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20200340A1 publication Critical patent/PE20200340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Referido a un compuesto de formula I; en donde A es un grupo de formula A.1 o A.2, en donde cada R1, R2, R3, R4, R5 y R6 son independientemente H, C1-C4 alquilo, entre otros; y B se selecciona del grupo B1, B.2 y B3, en donde R7 es H, C1-3-alquilo, halogeno, entre otros; R8 es C1-C6-alquilo, C3-C6-cicloalquilo, entre otros. Este compuesto es un inhibidor de vanina, siendo util en el tratamiento de enfermedades como enfermedad de Crohn y colitis ulcerosa. Tambien se refiere a procesos para la produccion de dichos compuestos y preparaciones farmaceuticas que los contienen.
PE2019002531A 2017-06-12 2018-06-08 Compuestos heteroaromaticos como inhibidores de vanina PE20200340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518106P 2017-06-12 2017-06-12
PCT/EP2018/065140 WO2018228934A1 (en) 2017-06-12 2018-06-08 Heteroaromatic compounds as vanin inhibitors

Publications (1)

Publication Number Publication Date
PE20200340A1 true PE20200340A1 (es) 2020-02-14

Family

ID=62631060

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002531A PE20200340A1 (es) 2017-06-12 2018-06-08 Compuestos heteroaromaticos como inhibidores de vanina

Country Status (23)

Country Link
US (2) US10364255B2 (es)
EP (1) EP3638680B1 (es)
JP (1) JP6880243B2 (es)
KR (1) KR102607934B1 (es)
CN (1) CN110770242B (es)
AR (1) AR112086A1 (es)
AU (1) AU2018285131B2 (es)
BR (1) BR112019021703A2 (es)
CA (1) CA3066946A1 (es)
CL (1) CL2019003515A1 (es)
CO (1) CO2019013823A2 (es)
DK (1) DK3638680T3 (es)
EA (1) EA039223B1 (es)
ES (1) ES2927021T3 (es)
HU (1) HUE060597T2 (es)
IL (1) IL271104B (es)
MA (1) MA49374A (es)
MX (1) MX2019014876A (es)
PE (1) PE20200340A1 (es)
PH (1) PH12019502693A1 (es)
PL (1) PL3638680T3 (es)
TW (1) TW201920196A (es)
WO (1) WO2018228934A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2927021T3 (es) * 2017-06-12 2022-11-02 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina
EP3837263A1 (en) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
DK3844161T3 (da) * 2018-08-28 2022-12-12 Boehringer Ingelheim Int Heteroaromatiske forbindelser som vanininhibitorer.
AR117229A1 (es) 2018-12-03 2021-07-21 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004018811D1 (de) * 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EP3303303A1 (en) * 2015-05-29 2018-04-11 Pfizer Inc Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
AU2017296338A1 (en) * 2016-07-14 2019-01-03 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
ES2927021T3 (es) * 2017-06-12 2022-11-02 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina

Also Published As

Publication number Publication date
EP3638680A1 (en) 2020-04-22
MX2019014876A (es) 2020-02-13
US10364255B2 (en) 2019-07-30
CA3066946A1 (en) 2018-12-20
IL271104B (en) 2022-03-01
CN110770242A (zh) 2020-02-07
CN110770242B (zh) 2022-08-19
PL3638680T3 (pl) 2022-12-19
AU2018285131B2 (en) 2021-11-11
WO2018228934A1 (en) 2018-12-20
AR112086A1 (es) 2019-09-18
DK3638680T3 (da) 2022-09-05
KR102607934B1 (ko) 2023-12-01
EA039223B1 (ru) 2021-12-20
BR112019021703A2 (pt) 2020-05-12
CL2019003515A1 (es) 2020-06-19
TW201920196A (zh) 2019-06-01
PH12019502693A1 (en) 2020-07-13
AU2018285131A1 (en) 2019-10-31
US20190263828A1 (en) 2019-08-29
MA49374A (fr) 2021-04-21
EP3638680B1 (en) 2022-08-10
ES2927021T3 (es) 2022-11-02
EA202090014A1 (ru) 2020-05-12
CO2019013823A2 (es) 2020-01-17
HUE060597T2 (hu) 2023-04-28
US20180354968A1 (en) 2018-12-13
JP2020522517A (ja) 2020-07-30
JP6880243B2 (ja) 2021-06-02
IL271104A (en) 2020-01-30
KR20200013718A (ko) 2020-02-07

Similar Documents

Publication Publication Date Title
PE20200340A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CL2019000512A1 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CL2018000338A1 (es) Derivados de heteroarilo como inhiidores de parp
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
CO2019007834A2 (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
CR20160478A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
PE20190979A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
EA201891644A1 (ru) Антибактериальные соединения и их применение
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
CU20160195A7 (es) Derivados de quinolizinona como inhibidores de pi3k
CU20160166A7 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
PH12016502568B1 (en) Novel heterocyclic compound